natgillin/translations-raw huggingface dataset:
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p &lt; 0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđen u 24. tjednu (36%, p = 0,0459), i MR ishode (nove/uvećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p &lt; 0,0001 za sve.)
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p &lt; 0.0001 for all).
Bolesnici izloženi Plegridyju svaka 2 tjedna pokazali su statistički značajna smanjenja u odnosu na bolesnike koji su bili izloženi Plegridyju svaka 4 tjedna tijekom 2 godine u post-hoc analizi ishoda uključujući ARR (24%, p=0,0209), rizik od relapsa (24%, p=0,0212), rizik od progresije onesposobljenosti potvrđenu 24. tjednu (36%, p = 0,0459), i MR ishode (nove/povećane T2 60%, Gd+ 71%, i nove T1 hipointenzivne lezije 53%; p &lt; 0,0001 za sve.)
Patients from birth to &lt; 2 months of age
Bolesnici od rođenja &lt; 2 mjeseca starosti
Patients had been receiving opioid therapy for pain (median daily baseline oral morphine equivalent dose = 160 mg) and had opioid-induced constipation ( &lt; 3 rescue medication-free bowel movements per week during the screening period).
Bolesnici su imali konstipaciju uzrokovanu opioidima ( &lt; 3 pražnjenja crijeva tjedno tijekom razdoblja probira bez primjene dodatnog laksativa).
Patients had opioid-induced constipation ( &lt; 3 rescue medication-free bowel movements per week during the screening period).
Bolesnici su imali konstipaciju uzrokovanu opioidima ( &lt; 3 pražnjenja crijeva tjedno tijekom razdoblja probira bez primjene dodatnog laksativa).
Patients had to be on either their first or second antiretroviral regimen with no history of virologic failure, have no current or past history of resistance to any of the three components of Eviplera, and must have been stably suppressed (HIV-1 RNA &lt; 50 copies/mL) for at least 6 months prior to screening.
Pacijenti su morali biti na ili svom prvom ili na drugom antivirusnom režimu bez anamneze virološkog neuspjeha, nisu smjeli imati sadašnju ili prethodnu rezistenciju ni na koju od tri komponente lijeka Eviplera i morali su imati stabilnu supresiju virusa (HIV-1 RNK &lt; 50 kopija/ml) tijekom najmanje 6 mjeseci prije probira.
Patients had to have been stably suppressed (HIV-1 RNA &lt; 50 copies/mL) for at least 6 months prior to screening.
U bolesnika je virus morao biti stabilno suprimiran (HIV-1 RNK &lt; 50 kopija/ml) tijekom najmanje 6 mjeseci prije probira.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mm Hg or a 10 mm Hg reduction in systolic pressure if baseline was &gt; 160 mm Hg.
Bolesnici u svim liječenim skupinama obično su uzimali između 2 i 4 antihipertenzivna lijeka (npr. diuretike, beta blokatore, alfa blokatore) kako bi postigli unaprijed definirani krvni tlak od ≤ 135/85 mmHg ili smanjenje sistoličkog tlaka za 10 mmHg ako je početna vrijednost bila &gt; 160 mmHg.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was &gt; 160 mmHg.
Bolesnici u svim liječenim skupinama obično su uzimali između 2 i 4 antihipertenzivna lijeka (npr. diuretike, beta blokatore, alfa blokatore) kako bi postigli unaprijed definirani krvni tlak od ≤ 135/85 mmHg ili smanjenje sistoličkog tlaka za 10 mmHg ako je početna vrijednost bila &gt; 160 mmHg.
Patients in steroid-free remission for &gt; = 90 daysa
Bolesnici u remisiji bez primjene steroida &gt; = 90 danaa
Patients in steroid-free remission for &gt; =90 daysa
Bolesnici u remisiji bez primjene steroida &gt; = 90 danaa
Patients in the 300 mg treatment groups achieved the highest mean proportion of angioedema-free days from week 4 to week 12, (91.0-96.1%; p &lt; 0.001) compared to the placebo groups (88.1-89.2%).
Bolesnici u terapijskoj skupini koja je primala 300 mg postigli su najviši srednji udio dana bez angioedema od 4. do 12. tjedna, (91,0-96,1%; p &lt; 0,001) u usporedbi s placebo skupinama (88,1-89,2%).
Patients in the Cimzia+MTX group had a greater reduction from baseline in DAS 28 (ESR) compared with the placebo+MTX group observed as early as Week 2 and continued through Week 52 (p &lt; 0.001 at each visit).
U bolesnika koji su primali Cimziju+MTX uočeno je veće smanjenje vrijednosti DAS28(ESR) u odnosu na početne vrijednosti u usporedbi sa skupinom koja je primala placebo+MTX već u 2. tjednu i nastavilo se do 52. tjedna (p &lt; 0,001 pri svakoj posjeti).
Patients in this study were required to be anaemic at Study entry (Hb &lt; 10.2 g/dl) and all patients were to receive oral iron 80 mg Fe++ in addition to study medicinal product.
Bolesnice u ovom ispitivanju trebale su biti anemične prilikom ulaska u ispitivanje (Hb &lt; 10,2 g/dl) i sve su trebale primati željezo peroralno 80 mg Fe++ pored ispitivanog lijeka.
Patients may be counted in more than one row. dICH=intracranial haemorrhage. eClinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but &lt; 5 g/dL.
Bolesnici mogu biti uključeni u više od jednog retka. dIKK=intrakranijalno krvarenje e Klinički zamjetno krvarenje udruženo s padom vrijednosti hemoglobina od ≥3 g/dl ali &lt; 5 g/dl.
Patients may be counted in more than one row. e ICH=intracranial haemorrhage. f Clinically overt bleeding associated with a fall in haemoglobin of ≥3 g/dL but &lt; 5 g/dL.
Bolesnici mogu biti uključeni u više od jednog retka. e IKK=intrakranijalno krvarenje f Klinički zamjetno krvarenje udruženo s padom hemoglobina od ≥ 3 g/dl, ali &lt; 5 g/dl.
Patients must have been stably suppressed (HIV-1 RNA &lt; 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry.
U bolesnika je HIV-1 morao biti stabilno suprimiran (HIV-1 RNK &lt; 50 kopija/ml) početnim reţimom najmanje 6 mjeseci i biti bez mutacija povezanih s rezistencijom na emtricitabin ili tenofoviralafenamid prije ulaska u ispitivanje.
Patients originally assigned to placebo and those in the daclatasvir group who did not achieve HCV RNA &lt; LLOQ at Week 4 and undetectable at Week 10 continued pegIFN/RBV to complete 48 weeks of treatment.
Bolesnici koji su izvorno randomizirani za primanje placeba i oni u skupini liječenoj daklatazvirom koji u 4. tjednu nisu imali HCV RNK &lt; LLOQ, niti nemjerljive razine HCV RNK u 10. tjednu, nastavili su liječenje kombinacijom pegIFN/RBV do ukupno 48 tjedana liječenja.
Patients over 60 years of age may be at greater risk for mild ( &gt; 3xULN) to severe ( &gt; 8xULN) elevation of ALT.
Bolesnici stariji od 60 godina mogu biti pod većim rizikom od blagog ( &gt; 3 x GGN) do teškog ( &gt; 8 x GGN) povećanja ALT-a.
Patients presenting end stage renal disease (creatinine clearance (CLCR &lt; 15 mL/min/1.73 m2), by their condition and the limited amount of data available should be treated with caution and monitored carefully during treatment (see sections 4.4 and 5.2).
Bolesnike koji su u terminalnoj fazi bubrežne bolesti (klirens kreatinina (CLCR &lt; 15 mL/min/1,73 m2), prema njihovom stanju i ograničenoj dostupnosti podataka treba liječiti uz oprez i pomno ih nadzirati tijekom liječenja (vidjeti dijelove 4.4 i 5.2).
Patients previously treated with anti-TNFα agents who received ustekinumab achieved a greater response at week 24 than patients receiving placebo (ACR 20 response at week 24 for 45 mg and 90 mg was 37% and 34%, respectively, compared with placebo 15%; p &lt; 0.05), and responses were maintained through week 52.
Bolesnici prethodno liječeni anti-TNFα lijekovima koji su primili ustekinumab dostigli su bolji odgovor u odnosu na placebo skupinu u 24. tjednu (ACR 20 odgovor u 24. tjednu za 45 mg odnosno 90 mg bio je 37% odnosno 34%, u usporedbi s placebom 15%; p &lt; 0,05), a odgovori su se održali kroz 52 tjedna.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (AF), tj. ili permanentnu AF ili najmanje 2 epizode intermitentne AF u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terapiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula &lt; 45% ili dokumentirana periferna vaskularna bolest.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (AF), tj. ili permanentnu AF ili najmanje 2 epizode intermitentne AF u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terpiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula &lt; 45% ili dokumentirana periferna vaskularna bolest.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (FA), tj. ili permanentnu FA ili najmanje 2 epizode intermitentne FA u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terapiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula &lt; 45% ili dokumentirana periferna vaskularna bolest.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE imali su dokumentiranu fibrilaciju atrija (FA), tj. ili permanentnu FA ili najmanje 2 epizode intermitentne FA u zadnjih 6 mjeseci te su imali najmanje jedan od sljedećih faktora rizika: dob ≥75 godina ili 55 do 74 godine te ili dijabetes koji zahtijeva terapiju lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; ako su primali terpiju za sistemsku hipertenziju; prethodni moždani udar, prolazni ishemijski napadaj (TIA) ili ne-CNS sistemska embolija; disfunkcija lijevog ventrikula s ejekcijskom frakcijom lijevog ventrikula &lt; 45% ili dokumentirana periferna vaskularna bolest.
Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age 75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; or documented peripheral vascular disease.
Bolesnici randomizirani u programu ACTIVE primljeni su uz dokumentiranu atrijsku fibrilaciju, tj. trajnu atrijsku fibrilaciju ili uz najmanje dvije epizode povremene atrijske fibrilacije tijekom zadnjih 6 mjeseci, te uz najmanje jedan od sljedećih faktora rizika: dob ≥ 75 godina ili dob od 55 do 74 godine uz dijabetes mellitus koji je potrebno tretirati lijekovima ili dokumentirani prethodni infarkt miokarda ili dokumentiranu bolest koronarnih arterija; liječeni zbog sistemske hipertenzija; prethodni moždani udar; tranzitorna ishemijska ataka ili sistemska embolija koja nije vezana uz središnji živčani sustav, disfunkcija lijeve klijetke uz izlaznu frakciju lijeve klijetke &lt; 45%; dokumentirana periferna vaskularna bolest.
Patients receiving acetylsalicylic acid &amp; clopidogrel as per protocol*
Bolesnici koji su primali acetilsalicilatnu kiselinu i klopidogrel prema planu ispitivanja
Patients receiving enzalutamide demonstrated a significantly higher total PSA response rate (defined as a ≥ 50% reduction from baseline), compared with patients receiving placebo, 78.0% versus 3.5% (difference = 74.5%, p &lt; 0.0001).
Bolesnici koji su primali enzalutamid pokazali su značajno višu ukupnu stopu odgovora PSA (definirano kao ≥ 50%-tno smanjenje u odnosu na početne vrijednosti), u usporedbi s bolesnicima koji su primali placebo, 78,0% naspram 3,5% (razlika = 74,5%, p &lt; 0,0001).
Patients reported in all the 3 Phase III trials a clinically meaningful pain relief within the first hour of treatment with Zalviso (pain intensity difference to baseline and total pain response &gt; 1 NRS).
Bolesnici su u sva 3 ispitivanja faze III prijavili klinički značajno ublažavanje boli unutar prvog sata liječenja Zalvisom (razlika u intenzitetu boli u odnosu na početne vrijednosti i ukupni odgovor na bol &gt; 1 numeričke ocjenske skale, engl. numeric rating skale, NRS).
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine /day may not find this regimen adequate.
Za bolesnike kojima je potrebna titrirana dnevna doza &gt; 8 mg buprenorfina/dan ovakav režim doziranja možda neće biti prikladan.
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine /day may not find this regimen adequate.
Za bolesnike kojima je potrebna titrirana dnevna doza &gt; 8 mg buprenorfina /dan ovakav režim doziranja možda neće biti prikladan.
Patients requiring a titrated daily dose &gt; 8 mg buprenorphine/day may not find this regimen adequate.
Za bolesnike kojima je potrebna titrirana dnevna doza &gt; 8 mg buprenorfina/dan ovakav režim doziranja možda neće biti prikladan.
Patients requiring larger LDL-C reduction ( &gt; 60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.
U bolesnika kojima je potrebno veće sniženje vrijednosti LDL-C ( &gt; 60%), liječenje može započeti dozom od 150 mg jednom svaka 2 tjedna ili 300 mg jednom svaka 4 tjedna ( jednom mjesečno), primijenjeno supkutano.
Patients studied were adults ( &gt; 18 years), with newly diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant, characterised, principally (54 of 60), as T1-T2, N0-N1, M0 (TNM classification).
U ispitivanju su sudjelovali odrasli bolesnici ( &gt; 18 godina) s novodijagnosticiranim diferenciranim papilarnim ili folikularnim karcinomom štitnjače, uključujući i papilarno-folikularni tip, koji su uglavnom (54 od 60) klasificirani kao T1-T2, N0-N1, M0 (TNM klasifikacija).
Patients transferring from a dose of &lt; 15 Units/kg imiglucerase were administered 15 Units/kg of velaglucerase alfa.
Bolesnici koji su prešli s doze od &lt; 15 jedinica/kg imigluceraze primili su 15 jedinica/kg velagluceraze alfa.
Patients treated with ALIMTA and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolesnici liječeni lijekom ALIMTA i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with Kentera experienced a highly statistically significant decrease in the number of urinary incontinence episodes per day from baseline to endpoint (the primary efficacy endpoint) compared with placebo (p &lt; 0.0001), as well as for the secondary endpoints: a decrease in the average daily urinary frequency (p=0.0017), and an increase in the average urine volume per void (p=0.0018).
Bolesnici koji su uzimali Kenteru imali su statistički vrlo značajno smanjenje u broju epizoda urinarne inkontinencije dnevno od početne vrijednosti do mjere ishoda (primarna mjera ishoda djelotvornosti) u usporedbi s placebom (p &lt; 0,0001), kao i za sekundarne mjere ishoda: smanjenje u prosječnoj dnevnoj učestalosti mokrenja (p=0,0017) i povećanje u prosječnom volumenu izmokrene mokraće pri mokrenju (p=0,0018).
Patients treated with liraglutide had a significant decrease in body weight compared to that of patients treated with sitagliptin (­2.9 kg and ­3.4 kg vs ­1.0 kg, p0.0001).
U bolesnika liječenih liraglutidom došlo je do značajnog smanjenja tjelesne težine u odnosu na bolesnike liječene sitagliptinom (-2,9 kg i -3,4 kg naspram -1,0 kg, p &lt; 0,0001).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4 % versus 28.9 %, p &lt; 0.001), red blood cell transfusions (16.1 % versus 27.3 %, p &lt; 0.001) and platelet transfusions (1.8 % versus 4.5 %, p = 0.002).
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4 % versus 28.9 %, p &lt; 0.001), red blood cell transfusions (16.1 % versus 27.3 %, p &lt; 0.001) and platelet transfusions (1.8 % versus 4.5 %, p=0.002).
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002).
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolesnici liječeni lijekom pemetreksed i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i transfuzija trombocita (1,8% naspram 4,5%, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p &lt; 0.001), red blood cell transfusions (16.1% versus 27.3%, p &lt; 0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Bolesnici liječeni pemetreksedom i cisplatinom trebali su manje transfuzija (16,4% naspram 28,9%, p &lt; 0,001), transfuzija eritrocita (16,1% naspram 27,3%, p &lt; 0,001) i manje transfuzija trombocita (1,8% naspram 4,5%, p=0,002).
Patients weighing &lt; 60 kg
Bolesnici tjelesne težine &lt; 60 kg
Patients were between 18 and 70 years of age and had active psoriatic arthritis ( 3 swollen joints and  3 tender joints) in at least one of the following forms: (1) distal interphalangeal (DIP) involvement; (2) polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3) arthritis mutilans; (4) asymmetric psoriatic arthritis; or (5) spondylitis- like ankylosis.
Bolesnici su bili u dobi od 18 do 70 godina te su imali aktivni psorijatični artritis ( &gt; 3 otečena zgloba i &gt; 3 bolna zgloba) u najmanje jednom od sljedećih oblika: (1) zahvaćenost distalnih interfalangealnih prostora (DIP), (2) poliartikularni artritis (izostanak reumatoidnih čvorića te prisutnost psorijaze), (3) artritis mutilans, (4) asimetrični psorijatični artritis ili (5) spondilitisu slična ankiloza.